pharmadog
News
when
  • Latest
  • Archive
by source
  • All Sources
  • Sources Page
Jobs
department
  • Clinical
  • Regulatory
  • Medical Affairs
  • Commercial
  • R&D / Discovery
  • Biostatistics / Data
  • Manufacturing / CMC
  • Market Access
therapeutic area
  • Oncology
  • Immunology
  • Neuroscience
  • Cardiovascular
  • Metabolic
  • Rare Disease
  • Infectious Disease
location & type
  • Remote Only
  • US Only
  • California
  • Massachusetts
  • Internships
  • Phase 3 Roles
  • All Jobs →
Drugs
by stage
  • Marketed
  • Phase 3
  • Phase 2
  • Phase 1
  • Preclinical
browse
  • Most catalysts
  • Recently active
  • All drugs →
  • Companies
  • Patent cliff
Calendar
what
  • Trial readouts
  • PDUFA dates
  • Approvals
  • Earnings
when
  • Upcoming
  • Month grid
  • Recently passed
Sign InSubscribe
pharmadog

fetch the data · sniff the signal

Discover
  • Jobs
  • News
  • Drugs
  • Calendar
  • Companies
Hubs
  • Topics
  • Patent cliff
  • Publications
  • Readouts
Tools
  • Compare
  • Search
  • Bookmarks
Trust
  • About
  • Sources
  • Contact
Legal
  • Privacy
  • Terms
  • Pricing

© 2026 pharmadog.xyz

made by humans and a good dog

  • home
  • jobs
  • news
  • search
  1. pharmadog
  2. ›drugs
  3. ›ENHERTU
drug
save

ENHERTU

updated 6mo ago
by Daiichi Sankyo Co Ltd
community read0 votes

🐶 often sniffed alongside

top 3
  • drugtrastuzumab deruxtecan78 co-mentions · 13 sources
  • tagApproval52 co-mentions · 13 sources
  • drugtrastuzumab26 co-mentions · 13 sources

all catalysts(0)

nothing on the calendar yet

Trials studying ENHERTU

  • phase2A Study of Trastuzumab Deruxtecan (T-DXd) and Cetuximab in People With Colorectal Cancernot yet recruitingn=27
  • phase2TAPUR: Testing the Use of Food and Drug Administration (FDA) Approved Drugs That Target a Specific Abnormality in a Tumor Gene in People With Advanced Stage Cancerrecruitingn=4,200
  • phase2Castrate Resistant Prostate Cancer Enhertu Therapyrecruitingn=60
  • phase1Neratinib and Fam-Trastuzumab Deruxtecan in Advanced Gastro-esophageal Cancer Patientsrecruitingn=18
  • phase1ELVN-002 in HER2 Mutant Non-Small Cell Lung Canceractive not recruitingn=198
  • phase2StrataPATH™ (Precision Indications for Approved Therapies)terminatedn=11

News(10)

  • BioNTech, DualityBio say ADC had ‘modest’ benefit in breast cancer study
    The companies said the findings suggest the treatment has a “limited” impact in HER2-low breast cancer, an area where AstraZeneca and Daiichi Sankyo’s Enhertu has already set a high bar.
    biopharma_dive · 24d ago
  • BioNTech sees ‘limited’ benefit to ADC after phase 3 reveals modest efficacy, ILD cases
    BioNTech has reported modest efficacy and unexpected safety findings in a phase 3 breast cancer trial, leading the company to conclude its HER2-directed candidate may offer limited benefits in the…
    fiercebiotech · 24d ago
  • ESMO: AstraZeneca exec insists phase 3 ADC data ‘robust’ enough for regulators despite PFS miss
    An AstraZeneca executive was adamant that detailed data from a phase 3 study of the pharma’s next-generation antibody-drug conjugate are “robust” enough to take to regulators, despite the trial fai…
    fiercebiotech · 26d ago
  • STAT+: England to cover AstraZeneca breast cancer drug, a result of U.K.-U.S. drug pricing deal
    A breast cancer drug from AstraZeneca will now be available in England after a pricing deal was reached, in part a result of the U.S.-U.K. pharma pact.
    stat · 2mo ago
  • WCLC ‘26: A new ‘ADC era,’ China questions and AstraZeneca’s spotlight
    The year’s biggest meeting on lung cancer research featured data suggesting a new treatment standard for an aggressive tumor as well as debate about the reliability of results from China-run studies.
    biopharma_dive · 2mo ago
  • Electra aims for nearly $300M IPO; Enhertu's Phase 3 lung cancer success
    Plus news about Lilly, Cellectis, Tyra, Shennon and QL Biopharm. Electra Therapeutics eyes $297M IPO: The Sanofi-backed biotech hopes to kick off the post-Labor Day IPO train with a nearly $300 mil…
    endpoints · 2mo ago
  • Unlocking cell surface protein research with site-specific labeling
    Applications in flow cytometry, cell sorting, target validation, and therapeutic discovery
    biospace · 2mo ago
  • Genentech doubles down on ADC-resistant cancers with $1B DualityBio pact
    Roche’s Genentech is paying DualityBio $45 million upfront for rights to antibody-drug conjugates (ADCs) designed for the growing pool of patients who progress after treatment with the modality. Th…
    fiercebiotech · 2mo ago
  • Jazz scores front-line gastric cancer nod from FDA for ‘practice-changing’ Ziihera
    Gastroesophageal adenocarcinoma presents the biggest market opportunity for Jazz Pharmaceuticals’ Ziihera, according to Truist Securities, which forecasts peak sales of the drug to reach $2.5 billion.
    biospace · 2mo ago
  • AstraZeneca touts separate late-stage lung cancer wins with Tagrisso, Enhertu
    AstraZeneca on Monday reported successes in two late-stage trials in different forms of lung cancer — one with a two-drug combination of Tagrisso and Orpathys and another with its blockbuster antib…
    endpoints · 3mo ago
view all news mentions →
brand
ENHERTU
generic
FAM-TRASTUZUMAB DERUXTECAN-NXKI
Data sources
ClinicalTrials.gov
last refreshed 7h ago
Found something off?
🐶 something off?

Report a data issue

Tell Bork what looks wrong — wrong sponsor, stale phase, mislinked ticker, anything. We’ll triage and fix.

comments(0)

5-min edit window · permanent after that
sign in to leave a comment · permanent archive after 5 minutes
no comments yet — first sniff?